KEY DEADLINES
Abstract Submission Deadline: CLOSED
Early Bird Registration Deadline: CLOSED
Accommodation Deadline: CLOSED
Standard Registration Deadline: 13 July 2022
KEY DEADLINES
Abstract Submission Deadline: CLOSED
Early Bird Registration Deadline: CLOSED
Accommodation Deadline: CLOSED
Standard Registration Deadline: 13 July 2022
The committee are pleased to announce the program overview is now available. This will continue to be updated as more details are confirmed, please note this is subject to change without notice. Please be aware the program is set to AEST.
9:00 – 10:30
Session 1: Opening Plenary
Chairs: Sharon Lewin and Gail Matthews
Welcome to Country
Michael West, Metropolitan Aboriginal Local Land Council, NSW
Committee Welcome
Sharon Lewin, Director, The Peter Doherty Institute Infection and Immunity, VIC
Government Welcome
Michael Kidd, Deputy Chief Medical Officer and Principal Medical Advisor
SARS CoV variants – how they are identified, and what is on the horizon?
Penny Moore, Wits University and the National Institute for Communicable Diseases, South Africa
Review key immune discoveries about SARS-CoV-2 and what we need to understand further
Amy Chung, Laboratory Head, Uni Melbourne, Doherty Institute, VIC
10:30 – 11:00
Morning Tea
11:00 – 12:30
Session 2: Long COVID
Long Covid – An Overview
Ziyad Al-Aly, VA Saint Louis Health Care System, United States
Pathogenesis / Causes of Long COVID
Prof Anthony Kelleher, Kirby Institute UNSW, NSW
Practical Management of Long COVID
Professor Greg Dore, Kirby Institute UNSW, NSW
Consumer Perspective – Q&A with Kailee Dyke and Greg Dore
Kaillee Dyke, VIC and Greg Dore, Kirby Institute UNSW, NSW
#17 Covid made long: examining the embodiment of the social and material effects of SARS-CoV-2 infection, adaptation and recovery
Kari Lancaster, UNSW, NSW
#75 Characterising inflammatory mechanisms in long COVID
Jane Sinclair, School Of Chemistry And Molecular Biosciences, The University Of Queensland
Discussion and Q&A
12:30 – 1:30
Lunch
12:45 – 1:15
Poster Tour Sessions
Poster Tour: Social, Political & Cultural Aspects
Tour guide: Sophie Adams
#42 #COVIDVACCINE: AN ANALYSIS OF TRENDING CONTENT ON TIKTOK
Susan Grantham, Griffith University, QLD
#35 LESSONS ABOUT COVID-19 VACCINE MESSAGING AND DELIVERY FOR MARGINALISED POPULATIONS/COMMUNITIES
Daniel Storer, Kirby Institute, NSW
#74 COVID-19 Toolkit Newsletter: An innovative and responsive resource for all people living with HIV in NSW
Craig Andrews, Positive Life, NSW
#26 Concerns about children returning to school in Victoria in 2022
Freya Saich, Burnet Institute, VIC
#88 All in this together? COVID responses, diverse communities and practices of care
Dean Murphy, Kirby Institute, UNSW, NSW & Dept Infectious Diseases, Alfred Hospital, VIC
Poster Tour: Clinical Management & Therapeutics
Tour guide: James McMahon
#76 EVALUATION OF THE SEEGENE ALLPLEX SARS COV-2 VARIANTS I ASSAY IN THE IDENTIFICATION OF SARS COV-2 OMICRON VARIANTS
Hayley Heaton, Canberra Health Services, ACT
#92 Covid 19 Outcomes Similar for People Living with HIV Compared with HIV Negatives in a Sydney General Practice
David Baker, East Sydney Doctors, NSW
#14 How do care environments shape COVID-19 healthcare?
Mia Harrison, University of New South Wales, NSW
1:30 – 3:00
Session 3: Enhancing vaccine development and manufacturing
Welcome to the session – 2 parts: Enhancing vaccine development and manufacturing and Learning from the COVID-19 pandemic
Kirsty Short, School of Chemistry and Molecular Biosciences, University of Queensland, QLD
Focus on development
Keith Chappell, University of Queensland, QLD
COVID vaccine trials and tribulations
Terry Nolan, Peter Doherty Institute for Infection and Immunity and MCRI, VIC
Focus on regulation
Kristine Macartney, The University of Sydney, NSW
Part 2: Learning from the COVID-19 pandemic
#15 BNT162B2 COVID-19 vaccine response in immunocompromised populations (Follicular Lymphoma and Waldenstrom’s Macroglobulinemia)
Priyanka Hastak, Kirby Institute UNSW, NSW
#61 Can vaccination prevent COVID-19 epidemics in Prison settings: a modelling study
Amy Kwon, The Kirby Institute, UNSW, NSW
#80 “Getting the vaccine makes me a champion of it.”: Understanding the motivations of Australians to talk about the COVID-19 vaccines to family and friends
Joshua Karras, UNSW, NSW
Discussion and Q&A
3:00 – 3:30
Afternoon Tea
3:30 – 5:00
Session 4: Therapy implementation
Chairs: Josh Davis and Krispin Hajkowicz
Australia’s National COVID-19 Evidence Taskforce: How it works, what treatments it recommends and why
Bridget Barber, QIMR Berghofer, QLD
Treatment options for SARS-CoV-2: the impact of virus evolution
Kanta Subbarao, WHO Collaborating Centre for Reference and Research on Influenza, VIC
What dose of heparin should be used in people hospitalised with COVID-19? First ever presentation of the
Australasian COVID—19 Trial (ASCOT) Anticoagulation Domain Results
Steve Tong, Doherty Institute, Melbourne Medical School, VIC
Results of a randomised controlled trial of Favipiravir for early symptomatic COVID-19: Results of the VIRCO Trial
James McMahon, Monash University, Alfred Health, VIC
Panel Discussion
6:30 – 9:30
Conference Dinner
9:00 – 10:30
Session 5: Morning Plenary
Chairs: Allen Cheng and TBC
Committee Welcome Day 2
Allen Cheng, Monash University, VIC
Global response to COVID – what can we learn from it? National health service – what was happening on the ground
Dr Muge Cevik, Division of Infection and Global Health Research, University of St Andrews, UK, UK
ROK’s COVID-19 responses
Yujin Jeong, Director of International Affairs, KCDC, South Korea
Discussion and Q&A
10:30 – 11:00
Morning Tea
11:00 – 12:30
Session 6 – Priority populations and communities
Chairs: Kari Lancaster and TBC
Responses in Aboriginal communities
Anna Ralph, Menzies School of Health Research, NT
Host susceptibility factors (e.g. age, obesity, diabetes, chronic inflammation) on viral disease, pandemic preparedness and anti-viral immunity
Kirsty Short, The University of Queensland, QLD
#77 When The Balanda Sickness Comes To Community: Continuing Respite Dialysis In The Midst Of A Community Outbreak
Georgia Corrie, Purple House, NT
#65 From lockdowns to mass vaccination: COVID-19 and health inequality
Adele Murdolo, Multicultural Centre For Women’s Health, VIC
#62 Aboriginal and Torres Strait Islander peoples and COVID-19: a national survey (Yarning About COVID) exploring beliefs, attitudes, and vaccination
Shea Spierings, Poche Center for Indigenous Health, University of Queensland, QLD
#34 Rethinking COVID-19 Outbreak Management Behind Bars
Camilla Lobo, Justice Health And Forensic Mental Health Network, NSW
#36 Experiences of the COVID-19 pandemic among people in Australia who inject drugs: Three years of cross-sectional survey data
Olivia Price, National Drug and Alcohol Research Centre, NSW
Discussion and Q&A
12:30 – 1:30
Lunch
12:45 – 1:15
Poster Tour Sessions
Poster Tour: Epidemiology, Prevention & Health Promotion
#63 The financial cost of COVID-19 in the Australian critical care system
Stefan Court-Kowals, Royal Adelaide Hospital, SA
#51 Characteristics of COVID-19 cases diagnosed using SARS-CoV-2 rapid antigen compared to PCR tests in Victoria, January – March 2022
Tu Quan Nguyen, Department Of Health, VIC
#91 Association between personal wellbeing and financial hardship among Victorian adults during the COVID pandemic
Aimée Altermatt, Burnet Institute, VIC
#69 SURVEILLANCE TESTING USING SALIVARY RT-PCR FOR SARS-COV-2 IN MANAGED QUARANTINE FACILITIES IN AUSTRALIA: A LABORATORY VALIDATION AND IMPLEMENTATION STUDY
Mitchell Batty, The Peter Doherty Institute For Infection And Immunity, VIC
#89 An integrative CALD community response to COVID-19
Natali Smud, Sydney Local Health District, NSW
Poster Tour: Discovery & Translational Science
#10 TOWARDS THE RAT AS A MODEL FOR COVID-19 LUNG DISEASE
Jill Carr, Flinders University, SA
#46 Impact of differential gene expression on early innate immune responses to COVID-19 vaccination in end stage renal disease patients and healthy controls
Shanelle Gingras, University Of Manitoba, Canada
#107 Identifying the neurological impact of COVID-19 in a mouse model of SARS-CoV-2 infection
Victoria Lawson, The University Of Melbourne, VIC
#11 BLOOD QUINOLINIC ACID AND KYNURENINE AS BIOMARKERS OF THERAPEUTIC TARGETS FOR NEUROCOVID
Bruce Brew, St Vincents Hospital Sydney, NSW
1:30 – 3:00
Session 7: Pandemic Preparedness & Modelling
How the UK response was established and what might have been done differently
Susan Michie, Centre for Behaviour Change at University College London, United Kingdom
Australian modelling for preparedness and response – working within and outside of government to inform policy
James Oates, Quantium Health, NSW and Emma McBryde, Australian Institute Of Tropical Health And Medicine, James Cook University, QLD
NSW response – how was the response established in a PHU? What is needed for next time?
Shopna Bag, Population Health, Centre for Population Health, NSW
Panel Discussion
#45 Designed for a pandemic: mitigating the risk of SARS-CoV-2 transmission through hospital design and infrastructure
Brendan Kennedy, Infectious Diseases Unit, Central Adelaide Local Health Network, SA
#83 Eliminating and learning to live with COVID-19: Modelling Australia’s way through the pandemic
Sophie Adam, UNSW, NSW
#66 The importance of an optimal strategy when responding to the Covid-19 pandemic: The NZ and Asia-Pacific Experience
Michael Baker, University Of Otago, New Zealand
#56 Evaluating the impact of the Cohealth Health Concierge program in public housing communities during the COVID-19 pandemic in Melbourne, Victoria
Jane Oliver, University Of Melbourne, VIC
3:00 – 3:30
Afternoon Tea
3:30 – 4:30
Session 8: Closing Plenary
Panel Discussion
Facilitator: Edwina Wright
Panellists: Mirabai McKellar-Nicholson, Edward Holmes, Sharon Lewin, Michael Baker, Heath Paynter and Vincent Cornelisse
Closing Remarks and People’s Choice Poster Award